Therapeutic Effects of Natural Products in Diabetic Retinopathy through Aldose Reductase Inhibition

Authors

  • Deokho Lee *

    The Korean Institute of Nutrition, Hallym University, Chuncheon 24252, South Korea
  • Livio Vitiello

    Eye Unit, “Luigi Curto” Hospital, Azienda Sanitaria Locale Salerno, 84035 Polla, Italy

DOI:

https://doi.org/10.55121/fds.v3i1.846

Keywords:

Natural Products, Diabetic Retinopathy, Aldose Reductase, Antioxidants, Reactive Oxygen Species, Phytochemicals

Abstract

Diabetic retinopathy (DR) is one of the most dangerous and cruel microvascular complications of diabetes, leading to visual impairment and blindness if left untreated. The development of DR is determined by complex multiple pathologic mechanisms, including oxidative stress, chronic inflammation, retinal vascular dysfunction, and retinal neuronal damage. Aldose reductase (AR) activation in the polyol pathway has been implicated to lead to excessive accumulation and production of reactive oxygen species (ROS) in several tissues (e.g., the heart, vasculature, kidney, and eye) under acute and chronic diabetic conditions. Therefore, many research scientists have extensively focused on developing synthetic AR inhibitors or finding AR inhibitors from natural products. Natural products and their bioactive compounds have been an important source of potential drugs to alleviate pathological conditions in various metabolic diseases. They are considered more effective, economical, convenient, and relatively safe. This review article aimed to focus on summarizing the therapeutic potential of natural product-based AR inhibitors for DR management. Many dietary compounds and phytochemicals have been found to be a good source of promising AR inhibitors. Their antioxidant effects can be used as a promising adjunctive treatment to conventional treatment (e.g., anti-vascular endothelial growth factor therapy) for DR management. Our comprehensive narrative review guides future research in drug discovery and development to modulate pathologic DR conditions.

References

[1] Nentwich, M.M., Ulbig, M.W., 2015. Diabetic retinopathy—ocular complications of diabetes mellitus. World Journal of Diabetes. 6(3), 489–499.

[2] Antar, S.A., Ashour, N.A., Sharaky, M., et al., 2023. Diabetes mellitus: Classification, mediators, and complications; a gate to identify potential targets for the development of new effective treatments. Biomedicine & Pharmacotherapy. 168, 115734.

[3] Wei, L., Sun, X., Fan, C., et al., 2022. The pathophysiological mechanisms underlying diabetic retinopathy. Frontiers in Cell and Developmental Biology. 10, 963615.

[4] Tomita, Y., Lee, D., Tsubota, K., et al., 2021. Updates on the current treatments for diabetic retinopathy and possibility of future oral therapy. Journal of Clinical Medicine. 10(20), 4666.

[5] Tomita, Y., Lee, D., Tsubota, K., et al., 2020. PPARα agonist oral therapy in diabetic retinopathy. Biomedicines. 8(10), 433.

[6] Lorenzi, M., 2007. The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient. Experimental Diabetes Research. 2007, 61038.

[7] Tang, W.H., Martin, K.A., Hwa, J., 2012. Aldose reductase, oxidative stress, and diabetic mellitus. Frontiers in Pharmacology. 3, 87.

[8] Apak, R., Calokerinos, A., Gorinstein, S., et al., 2022. Methods to evaluate the scavenging activity of antioxidants toward reactive oxygen and nitrogen species (IUPAC Technical Report). Pure and Applied Chemistry. 94(1), 87–144.

[9] Gulcin, İ., 2025. Antioxidants: A comprehensive review. Archives of Toxicology. 99(5), 1893–1997.

[10] Abdulghani, M.F., Al-Fayyadh, S., 2024. Natural products for managing metabolic syndrome: A scoping review. Frontiers in Pharmacology. 15, 1366946.

[11] Atanasov, A.G., Zotchev, S.B., Dirsch, V.M., et al., 2021. Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery. 20(3), 200–216.

[12] Vollmannová, A., Bojňanská, T., Musilová, J., et al., 2024. Quercetin as one of the most abundant represented biological valuable plant components with remarkable chemoprotective effects—A review. Heliyon. 10(12), e33342.

[13] Suganthy, N., Devi, K.P., Nabavi, S.F., et al., 2016. Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of actions. Biomedicine & Pharmacotherapy. 84, 892–908.

[14] Chaudhry, P.S., Cabrera, J., Juliani, H.R., et al., 1983. Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochemical Pharmacology. 32(13), 1995–1998.

[15] Varma, S.D., Mikuni, I., Kinoshita, J.H., 1975. Flavonoids as inhibitors of lens aldose reductase. Science. 188(4194), 1215–1216.

[16] Liu, Y., Gong, Y., Li, M., et al., 2024. Quercetin protects against hyperglycemia-induced retinopathy in Sprague Dawley rats by regulating the gut–retina axis and nuclear factor erythroid-2-related factor 2 pathway. Nutrition Research. 122, 55–67.

[17] Ho, T.-Y., Lo, H.-Y., Liu, I.-C., et al., 2020. The protective effect of quercetin on retinal inflammation in mice: The involvement of tumor necrosis factor/nuclear factor-κB signaling pathways. Food & Function. 11(9), 8150–8160.

[18] Xie, J., Song, W., Liang, X., et al., 2020. Protective effect of quercetin on streptozotocin-induced diabetic peripheral neuropathy rats through modulating gut microbiota and reactive oxygen species level. Biomedicine & Pharmacotherapy. 127, 110147.

[19] Chai, G.-R., Liu, S., Yang, H.-W., et al., 2021. Quercetin protects against diabetic retinopathy in rats by inducing heme oxygenase-1 expression. Neural Regeneration Research. 16(7), 1344–1350.

[20] Liu, W., Liu, P., Tao, S., et al., 2008. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Archives of Biochemistry and Biophysics. 475(2), 128–134.

[21] Paul, M., Hemshekhar, M., Kemparaju, K., et al., 2019. Berberine mitigates high glucose-potentiated platelet aggregation and apoptosis by modulating aldose reductase and NADPH oxidase activity. Free Radical Biology and Medicine. 130, 196–205.

[22] Fu, D., Yu, J.Y., Connell, A.R., et al., 2016. Beneficial effects of berberine on oxidized LDL-induced cytotoxicity to human retinal Müller cells. Investigative Ophthalmology & Visual Science. 57(7), 3369–3379.

[23] Zhai, J., Li, Z., Zhang, H., et al., 2020. Berberine protects against diabetic retinopathy by inhibiting cell apoptosis via deactivation of the NF-κB signaling pathway. Molecular Medicine Reports. 22(5), 4227–4235.

[24] Yoshikawa, M., Morikawa, T., Murakami, T., et al., 1999. Medicinal flowers. I. Aldose reductase inhibitors and three new eudesmane-type sesquiterpenes, kikkanols A, B, and C, from the flowers of Chrysanthemum indicum L. Chemical and Pharmaceutical Bulletin. 47(3), 340–345.

[25] Jung, S.H., Lee, J.M., Lee, H.J., et al., 2007. Aldose reductase and advanced glycation endproducts inhibitory effect of Phyllostachys nigra. Biological and Pharmaceutical Bulletin. 30(8), 1569–1572.

[26] Park, S.W., Cho, C.S., Jun, H.O., et al., 2012. Anti-angiogenic effect of luteolin on retinal neovascularization via blockade of reactive oxygen species production. Investigative Ophthalmology & Visual Science. 53(12), 7718–7726.

[27] Vähätupa, M., Järvinen, T.A.H., Uusitalo-Järvinen, H., 2020. Exploration of oxygen-induced retinopathy model to discover new therapeutic drug targets in retinopathies. Frontiers in Pharmacology. 11, 873.

[28] Lu, H.-E., Chen, Y., Sun, X.-B., et al., 2015. Effects of luteolin on retinal oxidative stress and inflammation in diabetes. RSC Advances. 5(7), 4898–4904.

[29] Ak, T., Gülçin, I., 2008. Antioxidant and radical scavenging properties of curcumin. Chemico-Biological Interactions. 174(1), 27–37.

[30] Du, Z.-Y., Bao, Y.-D., Liu, Z., et al., 2006. Curcumin analogs as potent aldose reductase inhibitors. Archiv der Pharmazie. 339(3), 123–128.

[31] Mirzaei, M., Harismah, K., Soleimani, M., et al., 2021. Inhibitory effects of curcumin on aldose reductase and cyclooxygenase-2 enzymes. Journal of Biomolecular Structure and Dynamics. 39(17), 6424–6430.

[32] Muthenna, P., Suryanarayana, P., Gunda, S.K., et al., 2009. Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance. FEBS Letters. 583(22), 3637–3642.

[33] Kondhare, D., Deshmukh, S., Lade, H., 2019. Curcumin analogues with aldose reductase inhibitory activity: Synthesis, biological evaluation, and molecular docking. Processes. 7(7), 417.

[34] Li, J., Wang, P., Zhu, Y., et al., 2015. Curcumin inhibits neuronal loss in the retina and elevates Ca²⁺/calmodulin-dependent protein kinase II activity in diabetic rats. Journal of Ocular Pharmacology and Therapeutics. 31(9), 555–562.

[35] Yang, F., Yu, J., Ke, F., et al., 2018. Curcumin alleviates diabetic retinopathy in experimental diabetic rats. Ophthalmic Research. 60(1), 43–54.

[36] Prasad, S., Tyagi, A.K., Aggarwal, B.B., 2014. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Research and Treatment. 46(1), 2–18.

[37] Boonrueng, P., Wasana, P.W.D., Vajragupta, O., et al., 2022. Combination of curcumin and piperine synergistically improves pain-like behaviors in mouse models of pain with no potential CNS side effects. Chinese Medicine. 17(1), 119.

[38] Ramalingam, N., Swaminathan, S., Ramalingam, R., 2025. Curcumin and piperine emulsomes as combinational treatment approach to enhance the anti-biofilm, anti-microbial, and wound healing activities of curcumin. Journal of Food Science and Technology. DOI: https://doi.org/10.1007/s13197-025-06327-7

[39] Flieger, J., Flieger, M., 2020. The [DPPH●/DPPH-H]-HPLC-DAD method on tracking the antioxidant activity of pure antioxidants and goutweed (Aegopodium podagraria L.) hydroalcoholic extracts. Molecules. 25(24), 6005.

[40] Zuo, G., Kim, H.-Y., Guillen Quispe, Y.N., et al., 2021. Valeriana rigida Ruiz & Pav. root extract: A new source of caffeoylquinic acids with antioxidant and aldose reductase inhibitory activities. Foods. 10(5), 1079.

[41] Ito, Y., 2005. Golden rules and pitfalls in selecting optimum conditions for high-speed counter-current chromatography. Journal of Chromatography A. 1065(2), 145–168.

[42] Ito, Y., 2013. pH-zone-refining counter-current chromatography: Origin, mechanism, procedure and applications. Journal of Chromatography A. 1271(1), 71–85.

[43] Zuo, G., Je, K.-H., Guillen Quispe, Y.N., et al., 2021. Separation and identification of antioxidants and aldose reductase inhibitors in Lepechinia meyenii (Walp.) Epling. Plants. 10(12), 2773.

[44] Huang, Y., Wu, Z., Ma, L., et al., 2025. Avicularin is a minor aldose reductase inhibitor in defatted seeds of Oenothera biennis L.: Screening, inhibitory kinetics, and interaction mechanism. Food Chemistry. 473, 143100.

[45] Julius, A., Renuka, R.R., Hopper, W., et al., 2022. Inhibition of aldose reductase by novel phytocompounds: A heuristic approach to treating diabetic retinopathy. Evidence-Based Complementary and Alternative Medicine. 2022(1), 9624118.

[46] Gakpey, M.E.L., Aidoo, S.A., Jumah, T.A., et al., 2025. Targeting aldose reductase using natural African compounds as promising agents for managing diabetic complications. Frontiers in Bioinformatics. 5, 1499255.

[47] Murata, M., Irie, J., Homma, S., 1994. Aldose reductase inhibitors from green tea. LWT – Food Science and Technology. 27(5), 401–405.

[48] Balestri, F., Poli, G., Pineschi, C., et al., 2020. Aldose reductase differential inhibitors in green tea. Biomolecules. 10(7), 1003.

[49] Boroughani, M., Tahmasbi, Z., Heidari, M.M., et al., 2024. Potential therapeutic effects of green tea (Camellia sinensis) in eye diseases, a review. Heliyon. 10(7), e28829.

[50] Veeresham, C., Rama Rao, A., Asres, K., 2014. Aldose reductase inhibitors of plant origin. Phytotherapy Research. 28(3), 317–333.

[51] Ahmad, S., Ahmad, M.F.A., Khan, S., et al., 2024. Exploring aldose reductase inhibitors as promising therapeutic targets for diabetes-linked disabilities. International Journal of Biological Macromolecules. 280, 135761.

[52] Ciorba, A.L., Saber, S., Abdelhamid, A.M., et al., 2025. Diabetic retinopathy in focus: Update on treatment advances, pharmaceutical approaches, and new technologies. European Journal of Pharmaceutical Sciences. 214, 107307.

[53] Lee, D., Miwa, Y., Kunimi, H., et al., 2022. HIF inhibition therapy in ocular diseases. The Keio Journal of Medicine. 71(1), 1–12.

[54] Kurihara, T., Westenskow, P.D., Friedlander, M., 2014. Hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) signaling in the retina. Advances in Experimental Medicine and Biology. 801, 275–281.

[55] Fang, J., Xia C, Cao Z, et al., 2005. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. The FASEB Journal. 19(3), 342–353.

[56] Liu, L.-Z., Fang, J., Zhou, Q., et al., 2005. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: Implication of chemoprevention of lung cancer. Molecular Pharmacology. 68(3), 635–643.

[57] Lee, C.S., Choi, E.Y., Lee, S.C., et al., 2015. Resveratrol inhibits hypoxia-induced vascular endothelial growth factor expression and pathological neovascularization. Yonsei Medical Journal. 56(6), 1678–1685.

[58] Ji, K., Li, Z., Lei, Y., et al., 2021. Resveratrol attenuates retinal ganglion cell loss in a mouse model of retinal ischemia reperfusion injury via multiple pathways. Experimental Eye Research. 209, 108683.

[59] Seong, H., Ryu, J., Jeong, J.Y., et al., 2015. Resveratrol suppresses vascular endothelial growth factor secretion via inhibition of CXC-chemokine receptor 4 expression in ARPE-19 cells. Molecular Medicine Reports. 12(1), 1479–1484.

[60] Yuan, D., Xu, Y., Xue, L., et al., 2024. Resveratrol protects against diabetic retinal ganglion cell damage by activating the Nrf2 signaling pathway. Heliyon. 10(9), e30786.

[61] Ruan, Y., Zhang, P., Jia, X., et al., 2024. Association of vitamin B6 intake with the risk and prognosis of diabetic retinopathy: A NHANES-based study. Clinical and Experimental Optometry. 107(8), 847–856.

[62] Ruamviboonsuk, V., Grzybowski, A., 2022. The roles of vitamins in diabetic retinopathy: A narrative review. Journal of Clinical Medicine. 11(21), 6490.

[63] Horikawa, C., Aida, R., Kamada, C., et al., 2020. Vitamin B6 intake and incidence of diabetic retinopathy in Japanese patients with type 2 diabetes: Analysis of data from the Japan Diabetes Complications Study (JDCS). European Journal of Nutrition. 59(4), 1585–1594.

[64] Smolek, M.K., Notaroberto, N.F., Jaramillo, A.G., et al., 2013. Intervention with vitamins in patients with nonproliferative diabetic retinopathy: A pilot study. Clinical Ophthalmology. 2013, 1451–1458.

[65] Ibuki, M., Lee, D., Shinojima, A., et al., 2020. Rice bran and vitamin B6 suppress pathological neovascularization in a murine model of age-related macular degeneration as novel HIF inhibitors. International Journal of Molecular Sciences. 21(23), 8940.

[66] Busik, J.V., 2021. Lipid metabolism dysregulation in diabetic retinopathy. Journal of Lipid Research. 62, 100017.

[67] Sun, W., Su, M., Zhuang, L., et al., 2024. Clinical serum lipidomic profiling revealed potential lipid biomarkers for early diabetic retinopathy. Scientific Reports. 14(1), 15148.

[68] Chen, K.-Y., Chan, H.-C., Chan, C.-M., 2025. Can fibrate therapy redefine the management of diabetic retinopathy? A comprehensive systematic review and meta-analysis of efficacy and safety. Journal of Diabetes and Its Complications. 39(11), 109178.

[69] Liu, M., Lim, S.T., Song, W., et al., 2025. Beyond lipids: Fenofibrate in diabetic retinopathy and nephropathy. Trends in Pharmacological Sciences. Available from: https://www.sciencedirect.com/science/article/pii/S0165614725001579

[70] Parra-Pineda, A., Lizarazo-Bocanegra, S., Villalba-Montero, L.F., et al., 2025. Fenofibrate and diabetic retinopathy. Diabetes Therapy. 16(9), 1763–1777.

[71] Lee, D., Tomita, Y., Negishi, K., et al., 2023. Therapeutic roles of PPARα activation in ocular ischemic diseases. Histology and Histopathology. 38(4), 391–401.

[72] Lee, D., Tomita, Y., Miwa, Y., et al., 2021. Fenofibrate protects against retinal dysfunction in a murine model of common carotid artery occlusion-induced ocular ischemia. Pharmaceuticals. 14(3), 223.

[73] Bogdanov, P., Hernández, C., Corraliza, L., et al., 2015. Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. Acta Diabetologica. 52(1), 113–122.

[74] Bae, K.-H., Kim, J.-G., Park, K.-G., 2014. Transcriptional regulation of fibroblast growth factor 21 expression. Endocrinology and Metabolism. 29(2), 105–111.

[75] Gälman, C., Lundåsen, T., Kharitonenkov, A., et al., 2008. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metabolism. 8(2), 169–174.

[76] Lee, D., Tomita, Y., Allen, W., et al., 2021. PPARα modulation-based therapy in central nervous system diseases. Life. 11(11), 1168.

[77] Fu, Z., Lundgren, P., Pivodic, A., et al., 2023. FGF21 via mitochondrial lipid oxidation promotes physiological vascularization in a mouse model of Phase I ROP. Angiogenesis. 26(3), 409–421.

[78] Fu, Z., Qiu, C., Cagnone, G., et al., 2021. Retinal glial remodeling by FGF21 preserves retinal function during photoreceptor degeneration. iScience. 24(4), 102376.

[79] Tomita, Y., Fu, Z., Wang, Z., et al., 2020. Long-acting FGF21 inhibits retinal vascular leakage in in vivo and in vitro models. International Journal of Molecular Sciences. 21(4), 1188.

[80] Fu, Z., Wang, Z., Liu, C.-H., et al., 2018. Fibroblast growth factor 21 protects photoreceptor function in type 1 diabetic mice. Diabetes. 67(5), 974–985.

[81] Fu, Z., Gong, Y., Liegl, R., et al., 2017. FGF21 administration suppresses retinal and choroidal neovascularization in mice. Cell Reports. 18(7), 1606–1613.

Downloads

Issue

Vol. 3 No. 1 (January 2026): In Progress

Section

Review

License

Copyright (c) 2026 Food and Drug Safety

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.